The currently available anti-CD20 mAb therapies for use in multiple sclerosis—rituximab, ocrelizumab, ofatumumab, and ublituximab—have led to significant improvements in disease outcomes through robust efficacy on clinical manifestations and MRI lesion activity, and are a cornerstone of highly effective disease-modifying treatment.

Adaptations of how these medications are used to reduce adverse effects are under investigation.

CNS-penetrant therapies are still needed to more effectively address the compartmentalized inflammation that is thought to play an important role in disability progression.